Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Eraxis: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Eraxis - General Information

Eraxis or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin. [Wikipedia]

 

Pharmacology of Eraxis

Eraxis is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Eraxis is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls. Eraxis is active in vitro against Candida albicans, C. glabrata, C. parapsilosis, and C. tropicalis.

 

Eraxis for patients

 

Eraxis Interactions

No clinically relevant drug-drug interactions have been observed with drugs likely to be co-administered with anidulafungin.

 

Eraxis Contraindications

Anidulafungin is contraindicated in persons with known hypersensitivity to anidulafungin, any component of anidulafungin, or other echinocandins.

 

Additional information about Eraxis

Eraxis Indication: For use in the treatment of the following fungal infections: Candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis) and esophageal candidiasis. Mechanism Of Action: Eraxis is a semi-synthetic echinocandin with antifungal activity. Eraxis inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3-β-D-glucan, an essential component of the fungal cell wall. Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Anidulafungin Synonyms: Not Available Drug Category: Antibiotics, Antifungal Drug Type: Small Molecule; Approved Other Brand Names containing Anidulafungin: Eraxis; Absorption: Not Available Toxicity (Overdose): During clinical trials a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose. No clinical adverse events were reported. The maximum non-lethal dose of anidulafungin in rats was 50 mg/kg, a dose which is equivalent to 10 times the recommended daily dose for esophageal candidiasis (50mg/day). Protein Binding: 84% Biotransformation: Hepatic metabolism of anidulafungin has not been observed. Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 (CYP450) isoenzymes. Anidulafungin undergoes slow chemical degradation at physiologic temperature and pH to a ring-opened peptide that lacks antifungal activity. Half Life: 40-50 hours Dosage Forms of Eraxis: Not Available Chemical IUPAC Name: Not Available Chemical Formula: C58H73N7O17 Anidulafungin on Wikipedia: https://en.wikipedia.org/wiki/Anidulafungin Organisms Affected: Aspergillis, Candida and other fungi